Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Down 0.9 %

Shares of NERV opened at $2.28 on Friday. Minerva Neurosciences has a 52-week low of $2.06 and a 52-week high of $13.49. The stock has a fifty day simple moving average of $2.26 and a two-hundred day simple moving average of $2.66. The company has a market capitalization of $15.94 million, a PE ratio of -5.18 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.